Automate Your Wheel Strategy on OGN
With Tiblio's Option Bot, you can configure your own wheel strategy including OGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OGN
- Rev/Share 18.081
- Book/Share 0.0035
- PB 2212.37
- Debt/Equity 9.7439
- CurrentRatio 1.7544
- ROIC 64.4595
- MktCap 2004337860.0
- FreeCF/Share 0.9941
- PFCF 7.7555
- PE 5.8753
- Debt/Assets 0.6514
- DivYield 0.0778
- ROE 0.7807
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | OGN | Piper Sandler | Overweight | Underweight | -- | $5 | Oct. 27, 2025 |
| Downgrade | OGN | Evercore ISI | Outperform | In-line | -- | -- | May 2, 2025 |
| Downgrade | OGN | JP Morgan | Neutral | Underweight | $18 | $20 | Sept. 6, 2024 |
News
Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Negative
Organon & Co. faces ongoing challenges, with shares down over 75% since debut and recent CEO resignation after inventory probe. OGN Q3 results show stagnant revenues, declining Women's Health sales, and persistent high debt, despite low valuation metrics like a 3.7x forward P/E. Dividend has been slashed, Nexplanon sales fell 50% in the US in Q3, and the company is selling assets to manage leverage and cash flow issues.
Read More
Organon Analysts Cut Their Forecasts Following Q3 Results
Published: November 11, 2025 by: Benzinga
Sentiment: Neutral
Organon (NYSE:OGN) reported better-than-expected earnings for the third quarter on Monday.
Read More
Organon (OGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Organon & Co. (OGN) Q3 2025 Earnings Call Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Organon & Co. ( OGN ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Jennifer Halchak - Head of Investor Relations Carrie Cox Joseph Morrissey - Interim CEO & Executive VP and Head of Manufacturing & Supply Matthew Walsh - Executive VP & CFO Conference Call Participants Jason Gerberry - BofA Securities, Research Division David Amsellem - Piper Sandler & Co., Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Terence Flynn - Morgan Stanley, Research Division Navann Ty Dietschi - BNP Paribas, Research Division …
Read More
Organon (OGN) Q3 Earnings and Revenues Beat Estimates
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.87 per share a year ago.
Read More
The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Organon & Co. shares plunged Monday, October 27th, after CEO Kevin Ali resigned amid an audit committee investigation into wholesaler sales irregularities. Despite the scandal, OGN's valuation at $7 per share is extremely cheap compared to peers, with a diversified product portfolio and global reach. The main risk is OGN's heavy $8.3 billion net debt load, which could hinder share price recovery if revenue growth remains sluggish.
Read More
Organon (OGN) Earnings Expected to Grow: Should You Buy?
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Read More
Kuehn Law Encourages Investors of Organon & Co. to Contact Law Firm
Published: September 09, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 9, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Organon & Co. (NYSE: OGN) breached their fiduciary duties to shareholders.
Read More
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Read More
Organon: Valuation Discount Offset By Structural Headwinds
Published: August 12, 2025 by: Seeking Alpha
Sentiment: Negative
Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines; cost-cutting helps margins, but can't reverse the downward trend in earnings. Valuation discounts already reflect worst-case scenarios; fair value is around $9 per share, leaving little upside unless growth drivers emerge.
Read More
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
OGN vs. HQY: Which Stock Is the Better Value Option?
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
Read More
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Negative
Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new products like Emgality and VTAMA are not offsetting losses from older drugs. Women's Health and Biosimilars show some growth, but not enough to reverse the overall negative trend or justify optimism.
Read More
Organon & Co. (OGN) Q2 2025 Earnings Call Transcript
Published: August 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Organon & Co. (NYSE:OGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Jennifer Halchak - Corporate Participant Juan Camilo Arjona Ferreira - Executive VP, Head of Research & Development and Chief Medical Officer Kevin Ali - CEO & Director Matthew M. Walsh - Executive VP & CFO Conference Call Participants Alexandra Doering von Riesemann - Piper Sandler & Co., Research Division Ethan Harris Brown - JPMorgan Chase & Co, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Terence C.
Read More
Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Organon (OGN) Beats Q2 Earnings and Revenue Estimates
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.12 per share a year ago.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Insights Into Organon (OGN) Q2: Wall Street Projections for Key Metrics
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Organon (OGN) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Organon (OGN) Expected to Beat Earnings Estimates: Should You Buy?
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Contact Levi & Korsinsky by July 22, 2025 Deadline to Join Class Action Against Organon & Co.(OGN)
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGN
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") (NYSE: OGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm
Published: July 21, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 21, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2024 and April 30, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 22, 2025.
Read More
OGN or MEDP: Which Is the Better Value Stock Right Now?
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
About Organon & Co. (OGN)
- IPO Date 2021-05-14
- Website https://www.organon.com
- Industry Drug Manufacturers - General
- CEO Kevin Ali
- Employees 10000